Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

Abstract Purpose Previous cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). In this prospective study, we report here the prognostic impact of pTKa in ER+/HER2− MBC pat...

Full description

Bibliographic Details
Main Authors: Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy, François-Clément Bidard
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Breast Cancer Research
Subjects:
Metastatic breast cancer
CDK4/6 inhibitor
Palbociclib
Thymidine kinase 1
Biomarker
Online Access:http://link.springer.com/article/10.1186/s13058-020-01334-2

Internet

http://link.springer.com/article/10.1186/s13058-020-01334-2

Similar Items